Recent Quotes (30 days)

You have no recent quotes
chg | %

Ipsen Biopharmaceuticals, Inc.

Find more results for Ipsen, Inc

Officers and directors

Sean McKercher
Paul Saatsoglou
Vice President Business Analytics, Comm Strategy and Operations
Donald Pearl
Vice President Research and Development


106 Allen Rd Ste 301
Basking Ridge, NJ 07920-3851
+1-908-275-6300 (Phone)
650-624-4940 (Fax)

Website links

Hey, cut Tercica some slack -- it's feeling a bit hormonal. The company's drug therapies focus on the treatment of growth disorders. The company's lead product Increlex (rhIGF-1) treats children with severe primary insulin-like growth factor deficiency, and its Somatuline Depot (lanreotide) is for the treatment of acromegaly (excess growth hormones) in adults. Cambrex Biosciences manufactures Increlex for the company. Tercica licenses manufacturing and other technology and intellectual property related to the recombinant growth hormone rhIGF-1 from Genentech. Tercica is a subsidiary of European drugmaker Ipsen.

Related companies